GLUCOSE SHEPHERD BLOOD GLUCOSE MONITORING SYSTEM
Device Facts
| Record ID | K102316 |
|---|---|
| Device Name | GLUCOSE SHEPHERD BLOOD GLUCOSE MONITORING SYSTEM |
| Applicant | Broadmaster Biotech Corporation |
| Product Code | CGA · Clinical Chemistry |
| Decision Date | Oct 7, 2011 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1345 |
| Device Class | Class 2 |
| Attributes | Pediatric |
Indications for Use
Glucose Shepherd Blood Glucose Monitoring System is intended for use outside the body (in vitro diagnostic use) at home. It is used for quantitative measurement of glucose level in fresh capillary whole blood samples (from the finger, the palm, the forearm, the upper arm, the calf and the thigh). The alternative site testing can be only used during steady-state blood glucose monitoring. The Glucose Shepherd Blood Glucose Monitoring System is intended for use by a single person and should not be shared. In addition, it is intended for use at home as an aid in monitoring the effectiveness of diabetes control program. It should not be used for the diagnosis or screening of diabetes, nor for the testing of neonates. The Glucose Shepherd Pro Blood Glucose Monitoring System is intended for use outside the body (in vitro diagnostic use). It is used for quantitative measurement of glucose level in fresh capillary whole blood samples (from the finger, the palm, the forearm, the upper arm, the calf and the thigh). The alternative site testing can be only used during steady-state blood glucose monitoring. The Glucose Shepherd Pro Blood Glucose Monitoring System may be used for multiple patients in a professional healthcare setting. It is intended for use as an aid in monitoring the effectiveness of diabetes control program. This system is only used with single-use, auto-disabling lancing devices. It should not be used for the diagnosis or screening of diabetes, for the testing of neonates, or for testing of arterial blood.
Device Story
System measures glucose in capillary whole blood via amperometric electrochemical method; glucose oxidase enzyme on test strip reacts with sample to produce electrical current proportional to glucose concentration. Meter measures current and ambient temperature to calculate glucose level. Used at home (single-patient) or professional settings (multi-patient). Requires 1.1 μL blood sample; results displayed in 5 seconds. Pro version requires single-use, auto-disabling lancing devices and disinfection between patients. Data can be linked to PC. Aids clinicians and patients in monitoring diabetes control effectiveness; not for diagnosis or screening. Benefits include rapid, quantitative glucose monitoring at various body sites during steady-state conditions.
Clinical Evidence
No clinical trials; performance established via bench testing and method comparison studies. Accuracy evaluated against YSI 2300 reference method using 114 patients (venous) and 99 patients (fingerstick/AST). Results met ISO 15197 criteria: 95% of results <75 mg/dL within ±15 mg/dL and ≥75 mg/dL within ±20% of reference. Precision studies (repeatability/intermediate) showed CVs <5%. Interference testing evaluated 18 substances; significant interference noted for acetaminophen, dopamine, levo-dopa, tolbutamide, gentisic acid, tolazamide, ascorbic acid, uric acid, ibuprofen, and mannose.
Technological Characteristics
Amperometric sensing using glucose oxidase enzyme. Power: two 1.5V AAA alkaline batteries. Hematocrit range: 20-60%. Operating conditions: 10°C-40°C, <85% R.H. Connectivity: PC link. Form factor: handheld meter.
Indications for Use
Indicated for quantitative measurement of glucose in fresh capillary whole blood (finger, palm, forearm, upper arm, calf, thigh) to monitor diabetes control effectiveness. Contraindicated for neonates, diabetes diagnosis/screening, and arterial blood testing. Pro version indicated for professional healthcare settings (multiple patients) using auto-disabling lancing devices.
Regulatory Classification
Identification
A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
Special Controls
*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
Predicate Devices
- Advocate Redi-Code Blood Glucose Monitoring System (k072039)
Related Devices
- K150052 — TRUE METRIX AIR Self-Monitoring Blood Glucose System, TRUE METRIX AIR PRO Professional Blood Gulcose Monitoring System · Nipro Diagnostics, Inc. · Mar 26, 2015
Submission Summary (Full Text)
{0}
1
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number:
k102316
B. Purpose for Submission:
New Device
C. Measurand:
Whole blood glucose
D. Type of Test:
Quantitative, Amperometric method, Glucose oxidase
E. Applicant:
BroadMaster Biotech Corporation
F. Proprietary and Established Names:
Glucose Shepherd Pro Blood Glucose Monitoring System,
Glucose Shepherd Blood Glucose Monitoring System,
Glucose Shepherd Pro Control Solution,
Glucose Shepherd Control Solution,
G. Regulatory Information:
| Device | Product Code | Classification | Regulation Section | Panel |
| --- | --- | --- | --- | --- |
| Glucose Shepherd Pro Blood Glucose Monitoring System | CGA | Class II | 21 CFR § 862.1345, Glucose test system, Glucose oxidase | 75-Chemistry |
| Glucose Shepherd Blood Glucose Monitoring System | CGA, NBW (over the | Class II | 21 CFR § 862.1345, Glucose test system, over the counter, Glucose | 75-Chemistry |
{1}
| | counter) | | oxidase, | |
| --- | --- | --- | --- | --- |
| Glucose Shepherd Control Solution | JJX | Class I, reserved | 21 CFR § 862.1660, Quality control material | 75- Chemistry |
H. Intended Use:
1. Intended use(s):
See indications for use below.
2. Indication(s) for use:
Device Name: Glucose Shepherd Blood Glucose Monitoring System
Glucose Shepherd Blood Glucose Monitoring System is intended for use outside the body (in vitro diagnostic use) at home. It is used for quantitative measurement of glucose level in fresh capillary whole blood samples (from the finger, the palm, the forearm, the upper arm, the calf and the thigh). The alternative site testing can be only used during steady-state blood glucose monitoring. The Glucose Shepherd Blood Glucose Monitoring System is intended for use by a single person and should not be shared. In addition, it is intended for use at home as an aid in monitoring the effectiveness of diabetes control program. It should not be used for the diagnosis or screening of diabetes, nor for the testing of neonates.
The Glucose Shepherd Blood Glucose Monitoring System consists of the Glucose Shepherd Blood Glucose meter and the Glucose Shepherd Blood Glucose test strips. The Glucose Shepherd Blood Glucose meter is used only with Glucose Shepherd Blood Glucose test strips to quantitatively measure glucose in fresh capillary whole blood samples drawn from finger tips, the palm, the forearm, the upper arm, the calf and the thigh.
The Glucose Shepherd Control Solutions are for use with the Glucose Shepherd Blood Glucose Monitoring System as a quality control check to verify the accuracy of blood glucose test results.
Device Name: Glucose Shepherd Pro Blood Glucose Monitoring System
Glucose Shepherd Pro Blood Glucose Monitoring System is intended for use outside the body (in vitro diagnostic use). It is used for quantitative measurement of glucose level in fresh capillary whole blood samples (from the finger, the palm, the forearm, the upper arm, the calf and the thigh). The alternative site testing can be only used during steady-state blood glucose monitoring. The Glucose Shepherd Pro Blood Glucose Monitoring System may be used for multiple patients in a professional healthcare setting. It is intended for use as an aid in monitoring the effectiveness of diabetes control program. This system is only used with single-use, auto-disabling lancing devices. It should not be used for the diagnosis or screening of diabetes, for the testing of neonates, or for testing of arterial blood.
{2}
The Glucose Shepherd Pro Blood Glucose Monitoring System consists of the Glucose Shepherd Pro Blood Glucose meter and the Glucose Shepherd Pro Blood Glucose test strips. The Glucose Shepherd Pro Blood Glucose meter is used only with Glucose Shepherd Pro Blood Glucose test strips to quantitatively measure glucose in fresh capillary whole blood samples drawn from finger tips, the palm, the forearm, the upper arm, the calf and the thigh.
The Glucose Shepherd Pro control solutions are for use with the Glucose Shepherd Pro Blood Glucose Monitoring System as a quality control check to verify the accuracy of blood glucose test results.
3. Special conditions for use statement(s):
Not for neonatal use, not for screening or diagnosis of diabetes mellitus.
Not for use on critically ill patients, patients in shock, severely hypotensive individuals, dehydrated patients or individuals experiencing hyperglycaemic-hyperosmolar state, with or without ketosis.
Alternative site testing (AST) should not be used to calibrate continuous glucose monitors (CGMs) nor for use in insulin dose calculations.
AST testing should only be done during steady-state times (when glucose is not changing rapidly).
Multiple user devices (Glucose Shepherd Pro Blood Glucose meter) must be disinfected between users following labeling recommendations.
Multiple patient use settings are to use disposable, single use lancing devices with the meters.
4. Special instrument requirements:
Glucose Shepherd Blood Glucose Meter
Glucose Shepherd Pro Blood Glucose Meter
I. Device Description:
The Glucose Shepherd Blood Glucose Monitoring System consists of a blood glucose meter, test strips, control solutions (Level 1, Level 2, and Level 3), lancing device, and commercially available sterilized lancets. This system utilizes an amperometric method to generate a current. The size of the current is proportional to the amount of glucose presented in the sample, providing a quantitative measure of glucose level in capillary whole blood.
The Glucose Shepherd Pro Blood Glucose Monitoring System consists of the Glucose Shepherd Pro Blood Glucose meter and the Glucose Shepherd Pro Blood Glucose test strips. Glucose Shepherd Pro Blood Glucose Monitoring System consists of a blood glucose meter, test strips, control solutions (Level 1, Level 2, and Level 3), and autodisabling single-use lancing devices. This system utilizes an amperometric method to generate a current. The size of the current is proportional to the amount of glucose level presented in the sample, providing a quantitative measure of glucose level in
3
{3}
capillary whole blood.
Glucose Shepherd control solutions are red aqueous solutions which contain 0.03% to 0.30% (w/v) glucose as an active ingredient and >99.7% (w/v) of inert ingredients. The Glucose Shepherd control solutions are available at three levels (Level 1, Level 2, and Level 3).
## J. Substantial Equivalence Information:
1. Predicate device name(s):
Advocate Redi-Code Blood Glucose Monitoring System
FORA Control Solution
2. Predicate 510(k) number(s):
k072039
k093724
3. Comparison with predicate:
The Glucose Shepherd Blood Glucose Monitoring System/ The Glucose Shepherd Pro Blood Glucose Monitoring System have the following similarities and differences to the predicate device:
| Items | Predicate Device | Candidate Devices | |
| --- | --- | --- | --- |
| Brand Name | Advocate Redi-Code Blood Glucose Monitoring System (k072039) | Glucose Shepherd Blood Glucose Monitoring System | Glucose Shepherd Pro Blood Glucose Monitoring System |
| Similarities | | | |
| Indications for Use | Intended for use in the quantitative measurement of glucose in fresh capillary whole blood from finger, palm, forearm, upper-arm, calf and thigh as an aid in monitoring the effectiveness of diabetes control program | Same | Same |
| Enzyme | Glucose Oxidase | Same | Same |
| Measurement principle | Amperometric method | Same | Same |
| Coding | No coding | Same | Same |
| Power | Two 1.5V AAA alkaline batteries | Same | Same |
| Test range | 20 mg/dL to 600 mg/dL | Same | Same |
| Hematocrit | 20% to 60% | Same | Same |
| Operating conditions | 50°F to 104°F (10°C to 40°C), below 85% R.H. | Same | Same |
{4}
| Items | Predicate Device | Candidate Devices | |
| --- | --- | --- | --- |
| Brand Name | Advocate Redi-Code Blood Glucose Monitoring System (k072039) | Glucose Shepherd Blood Glucose Monitoring System | Glucose Shepherd Pro Blood Glucose Monitoring System |
| Similarities | | | |
| Strip storage conditions | 39.2°F to 104°F (4°C to 40°C), below 85% R.H. | Same | Same |
| PC link | available | Same | Same |
| Differences | | | |
| Weight | 69.87g | 53g | |
| Dimension | 96mm (L) x 20mm (W) x 45mm (H) | 64mm (L) x 95mm (W) x 29mm (H) | |
| Test time | 7 seconds | 5 seconds | |
| Test volume | 0.7 μL | 1.1 μL | |
| Memory | 450 test results with day and time | 400 test results with optional before/after meal flags, and with day and time | |
| Glucose units | Either mg/dL or mmol/L | mg/dL | |
| Alarms | None | Six | |
| Pre-meal and post-meal flags | None | Yes | |
| | | | |
| Items | Predicate Device | Candidate Devices | |
| Brand Name | FORA Glucose Control Solution (k093724) | Glucose Shepherd control solution | Glucose Shepherd Pro control solution |
| Similarities | | | |
| Indications for Use | As a quality control check to verify the accuracy of blood glucose test results | Same | Same |
| Analyte | d-glucose | Same | Same |
| Matrix | Aqueous | Same | Same |
| Target Ranges | | | |
| Number of Levels | 3 Level 1: 64-92 mg/dL Level 2: 96-144 mg/dL Level 3: 280-420 mg/dL | Same | Same |
# K. Standard/Guidance Document Referenced (if applicable):
CEN 13640 Stability Testing of In Vitro Diagnostic Reagents
CLSI EP06-A Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline
CLSI EP07-A2 Interference Testing in Clinical Chemistry; Approved Guideline
IEC 60601-1-4, Medical Electrical Equipment, Part 1: General Requirements for Safety, 4. Collateral Standard: Programmable Electrical Medical Systems
{5}
IEC 61010-1 Safety requirements for electrical equipment for measurement, control, and laboratory use – Part 1: General requirements
IEC 61010-2-010 Safety requirements for electrical equipment for measurement, control, and laboratory use – Part 2-010: Particular requirements for laboratory equipment for the heating of materials
IEC 61326-1 Electrical equipment for measurement, control, and laboratory use – EMC requirements – Part 1: General requirements
IEC 61326-2-6 Electrical equipment for measurement, control, and laboratory use – EMC requirements – Part 2-6: Particular requirements - In vitro diagnostic (IVD) medical equipment
ISO 14971 Application of risk management to medical devices
ISO 15197 In vitro diagnostic test systems – Requirements for blood glucose monitoring systems for self-testing in managing diabetes mellitus
## L. Test Principle:
Glucose Shepherd Blood Glucose Monitoring System and Glucose Shepherd Pro Blood Glucose Monitoring System use an electrochemical method. It is based on the quantitative measurement of glucose in whole blood using an amperometric method, which detects the current produced from glucose oxidation. Glucose in the sample mixes with specific chemicals on the test strip producing a small amount of electrical current. The meter measures the current, as well as other important parameters, such as ambient temperature, and displays the corresponding blood glucose level in the sample. The strength of the current produced by the reaction depends on the amount of glucose in the blood sample.
## M. Performance Characteristics (if/when applicable):
### 1. Analytical performance:
#### a. Precision/Reproducibility:
Since the two Glucose Shepherd blood glucose monitoring systems are identical, only one set of precision studies were provided for both the systems.
The repeatability study was performed by one operator using heparinized anticoagulated whole blood (hematocrit ranged from 35% to 50%) at five different glucose concentrations. The final glucose concentrations for the blood samples were confirmed by YSI 2300. Each sample was tested on ten meters using three lots of test strips (three meters with each of the two test strips lots and four meters with one test strip lot). Ten measurements were obtained per meter and test strip lot, and glucose concentration (N=100 per concentration level). The results are summarized below:
{6}
Repeatability
| Range (mg/dL) | YSI (mg/dL) | Test Strip Lot # | Mean (mg/dL) | SD | CV% |
| --- | --- | --- | --- | --- | --- |
| 30-50 mg/dL | 44.4 | 1 | 40.4 | 1.91 | 4.71 |
| | | 2 | 40.6 | 2.01 | 4.96 |
| | | 3 | 41.2 | 1.93 | 4.69 |
| | | combined | 40.8 | 1.96 | 4.80 |
| 51-110 mg/dL | 75.8 | 1 | 87.0 | 4.06 | 4.66 |
| | | 2 | 84.9 | 4.17 | 4.91 |
| | | 3 | 87.8 | 3.89 | 4.43 |
| | | combined | 86.7 | 4.16 | 4.80 |
| 111-150 mg/dL | 136 | 1 | 144.7 | 4.09 | 2.83 |
| | | 2 | 142.5 | 4.40 | 3.09 |
| | | 3 | 144.7 | 3.50 | 2.42 |
| | | combined | 144.0 | 4.06 | 2.82 |
| 151-250 mg/dL | 228 | 1 | 246.1 | 3.98 | 1.62 |
| | | 2 | 245.4 | 4.50 | 1.83 |
| | | 3 | 245.8 | 3.69 | 1.50 |
| | | combined | 245.8 | 4.00 | 1.63 |
| 251-400 mg/dL | 376 | 1 | 349.5 | 9.03 | 2.58 |
| | | 2 | 354.6 | 8.90 | 2.51 |
| | | 3 | 358.9 | 9.45 | 2.63 |
| | | combined | 354.8 | 9.88 | 2.79 |
Intermediate precision studies were performed by one operator using three levels of control solutions. Each sample was tested on ten meters using three lots of test strips (three meters with each of the two test strip lots and four meters with one test strip lot) for ten days (N=100 per concentration level).
Intermediate Precision
| Control solution | Test Strip Lot # | Mean (mg/dL) | SD | CV% |
| --- | --- | --- | --- | --- |
| 64-92 mg/dL | 1 | 66.7 | 1.41 | 2.12 |
| | 2 | 66.6 | 1.74 | 2.61 |
| | 3 | 67.1 | 1.73 | 2.57 |
| | Combined | 66.8 | 1.64 | 2.46 |
| 96-144 mg/dL | 1 | 126.7 | 6.28 | 4.96 |
| | 2 | 120.9 | 4.75 | 3.93 |
| | 3 | 127.4 | 5.54 | 4.35 |
| | Combined | 125.2 | 6.21 | 4.96 |
| 280-420 mg/dL | 1 | 306.1 | 9.88 | 3.23 |
| | 2 | 307.8 | 9.63 | 3.13 |
| | 3 | 309.1 | 9.64 | 3.12 |
| | Combined | 307.8 | 9.69 | 4.96 |
{7}
b. Linearity/assay reportable range:
Linearity study was designed based on CLSI EP6-A guideline.
Since the two Glucose Shepherd blood glucose monitoring systems are identical, only one linearity study was provided for both the systems.
Nine heparinized venous blood samples spiked with dextrose that covered the range from 20-600 mg/dL (hematocrit 45%). Glucose concentrations were confirmed by the YSI-2300. One operator performed the study using one calibrated meter and one vial of test strips from one lot in quadruplicate (N=36 per test strip lot). The results are summarized below:
| Compared to YSI | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Replicate 1 | 0.9673 | 6.0271 | 0.9992 |
| Replicate 2 | 0.9616 | 8.4738 | 0.9984 |
| Replicate 3 | 0.9409 | 12.436 | 0.9957 |
| Replicate 4 | 0.9551 | 12.572 | 0.9972 |
The measurement range of the Glucose Shepherd Blood Glucose Monitoring Systems is 20 to 600 mg/dL.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Since the two Glucose Shepherd blood glucose monitoring systems are identical, only one set of traceability, value assignment and stability studies were provided for both the systems.
Glucose Shepherd Control Solutions:
Traceability and value assignment - The Glucose Shepherd control solutions are traceable to the N.I.S.T SRM 917c and the YSI-2300 analyzer. Value assignment was performed with 10 Glucose Shepherd blood glucose meters using 10 strips from six randomly selected vials of Glucose Shepherd blood glucose test strips from the same lot and three levels of control solutions. The mean, standard deviation and CV are calculated for each new lot of control material. If the three CVs are <5%, then the control range for each strip lot is calculated as mean ± 20% (for mean value ≥75 mg/dL) and mean ± 15 mg/dL (for mean value <75 mg/dL). If the CV is ≥ 5%, the product is judged defective and discarded.
Stability - The Glucose Shepherd control solutions are identical to FORA control solutions first commercialized under k041107, and more recently under k093724. The Glucose Shepherd control solutions are manufactured and labeled by the manufacturer. The stability study results provided were from the k041107.
Open vial control stability was tested at three control levels on two lots. Based on these studies, open vial stability is 90 days when stored tightly closed between 35°F and 86°F (2°C and 30°C). Unopened vial control stability was tested in real time at three control levels on three lots. Unopened
8
{8}
control solutions were tested under identical conditions as the opened control solutions. The unopened control solutions have a 24 month shelf life when stored between 35°F and 86°F (2°C and 30°C). Stability studies protocol and acceptance criteria for open and unopened vials were provided and found to be adequate.
## Glucose Shepherd Test Strips:
Stability - Real time stability was performed for Glucose Shepherd test strips to assess the shelf-life and open-vial stability of the test strips. Stability studies protocol and acceptance criteria were provided and found to be adequate. The sponsor claimed that the unopened test strips have a 24 month shelf-life and are stable for 3 months after opening when stored at temperatures between 39.2°F to 104°F (4°C to 40°C) at ≤ 85% R.H.
This information is provided in the labeling of the test strips and control materials.
## d. Detection limit:
The reportable range is 20 to 600 mg/dL based on the linearity/assay reportable range study above (section M.1.b).
## e. Analytical specificity:
Interference study was designed according to CLSI EP7-A2 guideline.
Since the two Glucose Shepherd Blood Glucose Monitoring Systems are identical, only one set of interference studies were provided for both systems.
Eighteen potential endogenous and exogenous interfering substances were evaluated by spiking heparinized venous blood with two levels of glucose concentrations within the ranges 80 - 120 mg/dL and 200 -300 mg/dL. The glucose samples were spiked with the potentially interfering compounds and tested on two meters using one test strip lot. Several concentrations of the interfering substances were tested as shown in the table below. Non interfering substances were tested at toxic level concentrations or 10 times the highest therapeutic concentrations as recommended in CLSI EP7-A2 guidance. The sugars with unknown blood concentration were tested at several concentrations up to 100 mg/dL (galactose and xylose) or 1000 mg/dL (maltose). If the blood concentration of the substance is not known, the concentration tested was three times the therapeutic dose distributed in 5L of blood. Bias was calculated as the mean percent difference in glucose reading between the test and control concentration groups. Significant interference is defined by the sponsor as a bias ≥ 10% of the test samples from the control group.
The sponsor claims no significant interference (< 10% difference) for the substances and concentrations shown in the table below:
9
{9}
| Interferent | Concentration tested (mg/dL) |
| --- | --- |
| Salicylate | 60.0 |
| Galactose | 100.0 |
| Maltose | 1000.0 |
| Xylose | 100.0 |
| Cholesterol | 500.0 |
| Creatinine | 15.0 |
| Triglycerides | 2000.0 |
| Methyl-Dopa | 2.5 |
| Bilirubin | 20.0 |
| Hemoglobin | 500.0 |
Interference was observed with the substances at and above the interfering concentrations listed below:
| Interferent | Interfering Concentration (mg/dL) | Concentrations tested (mg/dL) |
| --- | --- | --- |
| Acetaminophen | 12.5 | 3.6,12.5, 25.0, 50.0 |
| Dopamine | 3.0 | 1.5, 3.0, 6.5, 13.0 |
| Levo-Dopa | 4.0 | 1.0, 2.0, 3.0, 4.0, 12.0, 15.0, 20.0 |
| Tolbutamide | 150 | 7.2, 42.7, 80.0, 150.0 |
| Gentisic acid | 25.0 | 12.5, 25.0, 37.5, 50.0 |
| Tolazamide | 15.0 | 3.25, 7.5, 15.0, 30.0 |
| Ascorbic acid | 7.5 | 3.75, 5.83, 7.5, 15.0 |
| Uric Acid | 20.0 | 10.0, 15.0, 20.0, 25.2 |
| Ibuprophen | 50.0 | 2.0, 20.0, 40.0, 50.0 |
| Mannose | 250.0 | 50.0, 100.0, 250.0, 500.0 |
f. Assay cut-off:
Not applicable.
2. Comparison studies:
a. Method comparison with predicate device:
Accuracy Study using the Glucose Shepherd Pro Blood Glucose Monitoring System: The study was performed by healthcare professional at three sites over 10 days using heparinized venous blood samples from 114 patients. In addition, 3 venous samples were altered for blood glucose concentration less than 40 mg/dL and 3 venous samples were altered for blood glucose concentration greater than 400 mg/dL. The samples were tested using three lots of Glucose Shepherd Pro test strips and two Glucose Shepherd Pro meters. Distribution of glucose concentrations across the measuring range
{10}
was: 6 samples between 20 to $50\mathrm{mg / dL}$ , 18 samples between 50 to $80\mathrm{mg / dL}$ , 24 samples between 80 to $120\mathrm{mg / dL}$ , 36 samples between 120 to $200\mathrm{mg / dL}$ , 18 samples between 201 to $300\mathrm{mg / dL}$ , 12 samples between 301 to $400\mathrm{mg / dL}$ and 6 samples between 400 to $600\mathrm{mg / dL}$ . All results were compared to the YSI. The studies met ISO 15197 accuracy criteria, e.g. $95\%$ of glucose results $< 75\mathrm{mg / dL}$ were within $\pm 15\mathrm{mg / dL}$ of the reference method, and for samples $\geq 75\mathrm{mg / dL}$ , $95\%$ of results were within $\pm 20\%$ of the reference method. Results are summarized below:
Regression Analysis Healthcare Venous Blood vs YSI
| Test Strip | Meter | Slope | Intercept | R² |
| --- | --- | --- | --- | --- |
| Lot 1 | 1 | 0.963 | 3.127 | 0.988 |
| | 2 | 0.966 | 5.74 | 0.987 |
| Lot 2 | 1 | 0.968 | 3.930 | 0.986 |
| | 2 | 0.967 | 4.84 | 0.987 |
| Lot 3 | 1 | 0.961 | 4.617 | 0.986 |
| | 2 | 0.963 | 4.708 | 0.986 |
Healthcare Professional Venous Blood vs YSI $< 75\mathrm{mg / dL}$
| Test Strip | Meter | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- | --- |
| Lot 1 | 1 | 6/15(40%) | 11/15(73%) | 15/15(100%) |
| | 2 | 9/15(60%) | 14/15(93%) | 15/15(100%) |
| Lot 2 | 1 | 13/15(87%) | 15/15(100%) | 15/15(100%) |
| | 2 | 8/15(53%) | 14/15(93%) | 15/15(100%) |
| Lot 3 | 1 | 11/15(73%) | 14/15(93%) | 15/15(100%) |
| | 2 | 10/15(67%) | 14/15(93%) | 15/15(100%) |
Healthcare Professional Venous Blood vs YSI $\geq 75\mathrm{mg / dL}$
| Test Strip | Meter | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- | --- |
| Lot 1 | 1 | 43/105(41%) | 84/105(80%) | 99/105(94%) | 105/105(100%) |
| | 2 | 46/105(44%) | 89/105(85%) | 99/105(94%) | 105/105(100%) |
| Lot 2 | 1 | 41/105(39%) | 86/105(82%) | 101/105(96%) | 105/105(100%) |
| | 2 | 35/105(33%) | 86/105(82%) | 101/105(96%) | 105/105(100%) |
| Lot 3 | 1 | 49/105(47%) | 85/105(81%) | 103/105(98%) | 105/105(100%) |
| | 2 | 57/105(54%) | 92/105(88%) | 98/105(93%) | 105/105(100%) |
The Method Comparison study was performed by lay user and healthcare professional at three sites over 10 days using fresh finger stick capillary blood samples. Ninety nine patients participated in the study. Venous blood samples were collected in heparin tubes. Labeling was provided only in English and users followed it to perform testing. The samples were tested using three lots of Glucose Shepherd test strips. Distribution of glucose concentrations across the measuring range was: 5 samples between 20 to 50 mg/dL, 15 samples between 50 to 80 mg/dL, 20 samples between 80 to 120 mg/dL, 30 samples between 120 to 200 mg/dL, 15 samples between 201 to 300 mg/dL, 10 samples between 301 to 400 mg/dL and 4 samples between
{11}
400 to 600 mg/dL. All results were compared to the YSI. The studies met ISO 15197 accuracy criteria, e.g. 95% of glucose results < 75 mg/dL were within ± 15 mg/dL of the reference method, and for samples ≥ 75 mg/dL, 95% of results were within ± 20% of the reference method. Results are summarized below:
Regression Analysis Healthcare Professional Fingerstick vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 1.000 | -0.820 | 0.977 |
| Lot 2 | 1.034 | -4.110 | 0.979 |
| Lot 3 | 1.019 | -3.825 | 0.975 |
Healthcare Professional Fingerstick vs YSI < 75 mg/dL
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 10/13(77%) | 13/13(100%) | 13/13(100%) |
| Lot 2 | 9/13(69%) | 13/13(100%) | 13/13(100%) |
| Lot 3 | 12/13(92%) | 13/13(100%) | 13/13(100%) |
Healthcare Professional Fingerstick vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 39/86(45%) | 57/86(66%) | 77/86(90%) | 85/86(99%) |
| Lot 2 | 40/86(47%) | 64/86(74%) | 83/86(97%) | 86/86(100%) |
| Lot 3 | 39/86(45%) | 65/86(76%) | 78/86(91%) | 86/86(100%) |
Regression Analysis Lay User Fingerstick vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 0.969 | +2.343 | 0.990 |
| Lot 2 | 0.994 | -0.173 | 0.991 |
| Lot 3 | 1.001 | +0.327 | 0.983 |
Lay User Fingerstick vs YSI < 75 mg/dL
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 7/13(54%) | 13/13(100%) | 13/13(100%) |
| Lot 2 | 9/13(69%) | 11/13(85%) | 13/13(100%) |
| Lot 3 | 9/13(69%) | 11/13(85%) | 13/13(100%) |
Lay User Fingerstick vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 44/86(51%) | 75/86(87%) | 83/86(97%) | 86/86(100%) |
| Lot 2 | 48/86(56%) | 75/86(87%) | 85/86(99%) | 86/86(100%) |
| Lot 3 | 40/86(47%) | 66/86(77%) | 80/86(93%) | 85/86(99%) |
Alternative site testing for the palm, the forearm, the upper arm, the calf and the thigh was performed by lay users and healthcare providers. The study was performed at three sites over 10 days using capillary blood samples while the
12
{12}
participants were in steady-state. Ninety nine patients participated in the study. Venous blood samples were collected in heparin tubes. Labeling was provided only in English and users followed it to perform testing. The samples were tested using three lots of Glucose Shepherd test strips.
Distribution of glucose concentrations across the measuring range was: 5 samples between 20 to $50\mathrm{mg / dL}$ , 15 samples between 50 to $80\mathrm{mg / dL}$ , 20 samples between 80 to $120\mathrm{mg / dL}$ , 30 samples between 120 to $200\mathrm{mg / dL}$ , 15 samples between 201 to $300\mathrm{mg / dL}$ , 10 samples between 301 to $400\mathrm{mg / dL}$ and 4 samples between 400 to $600\mathrm{mg / dL}$ . All results were compared to the YSI. The studies met ISO 15197 accuracy criteria, e.g. $95\%$ of glucose results $< 75\mathrm{mg / dL}$ were within $\pm 15\mathrm{mg / dL}$ of the reference method, and for samples $\geq 75\mathrm{mg / dL}$ , $95\%$ of results were within $\pm 20\%$ of the reference method. Results are summarized below:
Regression Analysis Healthcare Professional Palm vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 1.049 | -5.972 | 0.954 |
| Lot 2 | 1.025 | -1.897 | 0.966 |
| Lot 3 | 0.995 | -3.030 | 0.951 |
Healthcare Professional Palm vs YSI $< 75\mathrm{mg / dL}$
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 4/13(31%) | 12/13(92%) | 13/13(100%) |
| Lot 2 | 6/13(46%) | 10/13(77%) | 13/13(100%) |
| Lot 3 | 7/13(54%) | 11/13(85%) | 13/13(100%) |
Healthcare Professional Palm vs YSI $\geq 75\mathrm{mg / dL}$
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 19/86(22%) | 40/86(47%) | 59/86(69%) | 84/86(98%) |
| Lot 2 | 24/86(28%) | 49/86(57%) | 68/86(79%) | 85/86(99%) |
| Lot 3 | 22/86(26%) | 43/86(50%) | 66/86(77%) | 85/86(99%) |
Regression Analysis Lay User Palm vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 0.987 | +3.191 | 0.980 |
| Lot 2 | 0.960 | +6.296 | 0.977 |
| Lot 3 | 0.992 | +4.803 | 0.976 |
Lay User Palm vs YSI $< 75\mathrm{mg / dL}$
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 3/13(23%) | 9/13(69%) | 13/13(100%) |
| Lot 2 | 5/13(38%) | 8/13(62%) | 13/13(100%) |
| Lot 3 | 6/13(46%) | 10/13(77%) | 13/13(100%) |
{13}
Lay User Palm vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 36/86(42%) | 59/86(69%) | 75/86(87%) | 82/86(95%) |
| Lot 2 | 32/86(37%) | 66/86(77%) | 78/86(91%) | 83/86(97%) |
| Lot 3 | 33/86(38%) | 57/86(66%) | 73/86(85%) | 84/86(98%) |
Regression Analysis Healthcare Professional Forearm vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 0.999 | + 2.217 | 0.951 |
| Lot 2 | 1.001 | - 0.065 | 0.962 |
| Lot 3 | 0.951 | + 8.097 | 0.949 |
Healthcare Professional Forearm vs YSI < 75 mg/dL
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 4/13(31%) | 11/13(85%) | 13/13(100%) |
| Lot 2 | 9/13(69%) | 13/13(100%) | 13/13(100%) |
| Lot 3 | 3/13(23%) | 11/13(85%) | 13/13(100%) |
Healthcare Professional Forearm vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 22/86(26%) | 42/86(49%) | 59/86(69%) | 84/86(98%) |
| Lot 2 | 21/86(24%) | 48/86(56%) | 72/86(84%) | 85/86(99%) |
| Lot 3 | 23/86(27%) | 45/86(52%) | 63/86(73%) | 85/86(99%) |
Regression Analysis Lay User Forearm vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 0.981 | + 0.040 | 0.974 |
| Lot 2 | 0.955 | + 3.611 | 0.981 |
| Lot 3 | 0.981 | + 0.040 | 0.974 |
Lay User Forearm vs YSI < 75 mg/dL
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 8/13(62%) | 10/13(77%) | 13/13(100%) |
| Lot 2 | 7/13(54%) | 10/13(77%) | 13/13(100%) |
| Lot 3 | 4/13(31%) | 9/13(69%) | 13/13(100%) |
Lay User Forearm vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 38/86(44%) | 62/86(72%) | 73/86(85%) | 84/86(98%) |
| Lot 2 | 31/86(36%) | 62/86(72%) | 74/86(86%) | 85/86(99%) |
| Lot 3 | 31/86(36%) | 52/86(60%) | 71/86(83%) | 83/86(97%) |
{14}
Regression Analysis Healthcare Professional Upper arm vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 0.992 | + 1.012 | 0.953 |
| Lot 2 | 0.965 | + 3.959 | 0.951 |
| Lot 3 | 1.050 | - 7.418 | 0.966 |
Healthcare Professional Upper arm vs YSI < 75 mg/dL
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 3/13(23%) | 12/13(92%) | 13/13(100%) |
| Lot 2 | 5/13(38%) | 11/13(85%) | 13/13(100%) |
| Lot 3 | 5/13(38%) | 9/13(69%) | 13/13(100%) |
Healthcare Professional Upper arm vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 22/86(26%) | 41/86(48%) | 65/86(76%) | 85/86(99%) |
| Lot 2 | 22/86(26%) | 41/86(48%) | 61/86(71%) | 83/86(97%) |
| Lot 3 | 23/86(27%) | 40/86(47%) | 66/86(77%) | 86/86(100%) |
Regression Analysis Lay User Upper arm vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 0.966 | + 0.945 | 0.960 |
| Lot 2 | 0.930 | + 5.965 | 0.962 |
| Lot 3 | 0.956 | + 3.116 | 0.968 |
Lay User Upper arm vs YSI < 75 mg/dL
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 6/13(46%) | 10/13(77%) | 13/13(100%) |
| Lot 2 | 6/13(46%) | 9/13(69%) | 13/13(100%) |
| Lot 3 | 6/13(46%) | 8/13(62%) | 13/13(100%) |
Lay User Upper arm vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 16/86(19%) | 43/86(50%) | 69/86(80%) | 83/86(97%) |
| Lot 2 | 24/86(28%) | 48/86(56%) | 70/86(81%) | 83/86(97%) |
| Lot 3 | 28/86(33%) | 49/86(57%) | 71/86(83%) | 83/86(97%) |
Regression Analysis Healthcare Professional Calf vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 0.910 | + 8.854 | 0.957 |
| Lot 2 | 0.969 | + 4.297 | 0.939 |
| Lot 3 | 0.964 | + 3.749 | 0.958 |
{15}
Healthcare Professional Calf vs YSI < 75 mg/dL
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 7/13(54%) | 12/13(92%) | 13/13(100%) |
| Lot 2 | 4/13(31%) | 9/13(69%) | 13/13(100%) |
| Lot 3 | 9/13(69%) | 13/13(100%) | 13/13(100%) |
Healthcare Professional Calf vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 28/86(33%) | 50/86(58%) | 66/86(77%) | 85/86(99%) |
| Lot 2 | 16/86(19%) | 38/86(44%) | 53/86(62%) | 84/86(98%) |
| Lot 3 | 24/86(28%) | 45/86(52%) | 66/86(77%) | 84/86(98%) |
Regression Analysis Lay User Calf vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 0.960 | + 5.430 | 0.965 |
| Lot 2 | 0.983 | + 2.076 | 0.973 |
| Lot 3 | 0.946 | + 9.490 | 0.969 |
Lay User Calf vs YSI < 75 mg/dL
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 6/13(46%) | 11/13(85%) | 13/13(100%) |
| Lot 2 | 7/13(54%) | 13/13(100%) | 13/13(100%) |
| Lot 3 | 6/13(46%) | 11/13(85%) | 13/13(100%) |
Lay User Calf vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 31/86(36%) | 53/86(62%) | 71/86(83%) | 85/86(99%) |
| Lot 2 | 36/86(42%) | 56/86(65%) | 74/86(86%) | 85/86(99%) |
| Lot 3 | 26/86(30%) | 51/86(59%) | 72/86(84%) | 84/86(98%) |
Regression Analysis Healthcare Professional Thigh vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 1.003 | -0.926 | 0.970 |
| Lot 2 | 1.038 | -6.814 | 0.962 |
| Lot 3 | 1.040 | -5.792 | 0.964 |
Healthcare Professional Thigh vs YSI < 75 mg/dL
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 5/13(38%) | 12/13(92%) | 13/13(100%) |
| Lot 2 | 8/13(62%) | 10/13(77%) | 13/13(100%) |
| Lot 3 | 7/13(54%) | 10/13(77%) | 13/13(100%) |
{16}
Healthcare Professional Thigh vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 27/86(31%) | 52/86(60%) | 67/86(78%) | 86/86(100%) |
| Lot 2 | 25/86(29%) | 41/86(48%) | 59/86(69%) | 84/86(98%) |
| Lot 3 | 24/86(28%) | 46/86(53%) | 69/86(80%) | 85/86(99%) |
Regression Analysis Lay User Thigh vs YSI
| Test Strip | Slope | Intercept | R² |
| --- | --- | --- | --- |
| Lot 1 | 0.949 | + 3.698 | 0.970 |
| Lot 2 | 0.930 | + 5.260 | 0.961 |
| Lot 3 | 0.964 | + 3.338 | 0.955 |
Lay User Thigh vs YSI < 75 mg/dL
| Test Strip | Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- | --- |
| Lot 1 | 5/13(38%) | 12/13(92%) | 13/13(100%) |
| Lot 2 | 6/13(46%) | 10/13(77%) | 13/13(100%) |
| Lot 3 | 7/13(54%) | 13/13(100%) | 13/13(100%) |
Lay User Thigh vs YSI ≥ 75 mg/dL
| Test Strip | Within ± 5% | Within ± 10% | Within ± %15 | Within ± 20% |
| --- | --- | --- | --- | --- |
| Lot 1 | 34/86(40%) | 54/86(63%) | 70/86(81%) | 84/86(98%) |
| Lot 2 | 30/86(35%) | 50/86(58%) | 65/86(76%) | 83/86(97%) |
| Lot 3 | 25/86(29%) | 47/86(55%) | 66/86(77%) | 83/86(97%) |
b. Matrix comparison:
Not applicable.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
{17}
18
5. Expected values/Reference range:
Expected blood glucose values for normal people without diabetes is cited from the literature¹ and presented in the labeling as follows:
Fasting and before meal: 70 to 130 mg/dL
1-2 hours after meal: Less than 180 mg/dL
¹American Diabetes Association (2010), Standards of Medical Care in Diabetes.
Diabetes Care 33 (Supplement 1): S11-S61.
N. Instrument Name:
Glucose Shepherd Blood Glucose meter
Glucose Shepherd Pro Blood Glucose meter
O. System Descriptions:
1. Modes of Operation:
Each test strip is single use and requires a sample volume of 1.1 μL.
Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?
☐ Yes ☑ X or No
Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?
☐ Yes ☑ X or No
2. Software:
FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:
☐ Yes ☑ X or No
3. Specimen Identification:
There is no sample identification function with this device. Samples are applied directly to the test strip as they are collected.
4. Specimen Sampling and Handling:
The glucose test is intended to be used with capillary whole blood from the finger, the palm, the forearm, the upper arm, the calf and the thigh. The whole blood sample is applied directly to the test strip by capillary action.
{18}
19
5. Calibration:
The Glucose Shepherd Blood Glucose meter is a no code device. Reaction intensities of new test strip lots must meet the manufacturer's no code criteria for use with these meters. Validation of new strip lots is confirmed by comparison to the YSI across the measuring range of the device.
6. Quality Control:
Glucose control solutions at three concentration levels can be run with this device. The meter has an algorithm to automatically recognize the control solutions to prevent control results from being stored in the internal memory as patient result. Recommendations on when to test the control materials are provided in the labeling. The control solution readings are not included in the average of the patient results. An acceptable range for each control level is printed on the test strip vial label. The user is cautioned not to use the meter if the control result falls outside these ranges.
P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:
1. A usability study was performed to assess the readability of the labeling by recruiting 99 lay users (aged 22-72 yrs old) who were provided with the test kit containing labeling in English for the US market. Participants varied in age, education, country of origin, and were about evenly divided between men and women. These lay users also completed a questionnaire to indicate whether the device is easy to use and the Instructions for use were written in a way that makes it easy to use. The majority of the users responded that the device is very easy to use.
2. Flesch-Kincaid readability assessment was conducted and the results showed that the labeling (User Guide, test strip package insert and control solution package insert) were written at grade levels ranging from 7.0th to 8.0th grade.
3. Customer service is available Monday to Friday between 8:30 AM to 4:30 PM CST. Toll free phone number is 1-877-394-1655 for customer support.
4. Insufficient sample studies were performed at volumes starting from 0.3 µL to 2.0 µL in increments of 0.1 µL around the recommended volume (1.1 µL) using six vials of test strips from one lot. Each sample was tested six times per strip lot. Three glucose concentration levels of venous whole blood were tested (49 mg/dL, 159 mg/dL and 248 mg/dL) as determined by the YSI. Appropriate sample volume was determined if the meter results compared to YSI results were within 10% bias for blood samples. A blood volume ≥ 1.1 µL met the criteria.
5. Temperature and humidity operating conditions were evaluated for temperatures ranging from 50°F to 104°F (10°C to 40°C) and relative humidity below 85% R.H. The sponsor tested combinations of lowest and highest temperatures with lowest
{19}
and highest humidity levels. The study protocol and acceptance criteria were provided and found to be acceptable. The results supported the Sponsor's claimed operating temperature from 50°F to 104°F (10°C to 40°C) and relative humidity below 85%.
6. The effect of altitude on the accuracy of the device was evaluated on the Glucose Shepherd Blood Glucose Monitoring System with two meters and four vials of test strips from one lot. Venous blood samples at five concentrations of glucose (50-100mg/dL, 101-150mg/dL, 151-200mg/dL, 250-300mg/dL and 400-450mg/dL) were tested at three altitude levels (3,328, 8,478 and 10,745 feet) and at sea level (22.97 feet). Each sample was also tested by YSI-2300. No significant interference from altitude was defined by the sponsor as bias within ±10%. The data demonstrates that elevation of 10,745 feet does not affect the accuracy of the device. Based on the data, the sponsor claims that the Glucose Shepherd Blood Glucose Monitoring System can be used at altitude up to 10,745 feet.
7. The Glucose Shepherd Pro Blood Glucose Monitoring System is intended for multiple patient use by healthcare professionals and the Glucose Shepherd Blood Glucose Monitoring System is intended for home use by single person. Disinfection studies were performed on the Glucose Shepherd meter and lancing device to determine the robustness of the meter and lancing device to the recommended cleaning and disinfection protocol, and its effectiveness in preventing the spread of bloodborne pathogens, particularly hepatitis B virus (HBV). CaviWipesXL (CW) disposable wipes (EPA Reg. No.46781-8) was validated, demonstrating complete inactivation of live virus for use with the Glucose Shepherd meter and lancing device. The sponsor demonstrated that there was no change in performance or in the external materials of the Glucose Shepherd meter after 15,000 cleaning and disinfection cycles to simulate an estimated 8 to 9 cleaning and disinfection cycles per day over 5 years of healthcare professional use. The sponsor demonstrated that there was no change in performance or in the external materials of the lancing after 3,000 cleaning and disinfection cycles. The labeling states that the meter must be replaced with a new meter at the end of 15,000 cleaning and disinfection cycles or 5 years, whichever comes first. The lancing device must be replaced with a new lancing device at the end of 5,000 cleaning and disinfection cycles or 1 year, whichever comes first. Labeling has been reviewed for adequate instructions on the validated cleaning and disinfection procedures.
8. EMC testing was evaluated and certified by TUV Rheinland LGA Products GmbH and a certificate of conformity was issued to BroadMaster Biotech Corporation on 03-08-2010.
9. The effect of different hematocrit levels on the accuracy of the device was evaluated on the Glucose Shepherd Blood Glucose Monitoring System using two meters (tested in duplicate) and twelve vials of test strips from one lot. Blood
20
{20}
samples at nine hematocrit levels from 20% to 60% (20, 25, 30, 35, 40, 45, 50, 55 and 60%) were evaluated in eight concentrations of glucose of approximately 20, 50, 100, 200, 300, 400, 500 and 600 mg/dL. Glucose concentrations were compared to YSI and to 40% hematocrit. No significant interference from hematocrit was defined as bias within ± 15%. Results demonstrated that hematocrit levels between 20%-60% do not significantly interfere with glucose measurements.
Q. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
R. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
21
